An Independent Biotechnology company with experienced clinicians and scientists

Professor Alastair G. Sutcliffe is a clinician scientist and consultant paeditirican, with extensive experience in paediatrics and child health and holds a part-time academic appointment at University College London (UCL). He has led and contributed to numerous clinical trials and is widely recognised for his expertise in human fertility–related research. Professor Sutcliffe is a joint patentee of a novel mucoadhesive gel designed to normalise the vaginal microbiome, initially developed for the treatment of bacterial vaginosis. A long-term iteration of this technology is intended for application in reducing premature births associated with ascending infection in low- and middle-income countries (LMICs) and globally.

Professor Long Lin received his BSc (1983) and MSc (1986) from Zhejiang University, and his PhD (1994) from the University of Leeds, specialising throughout in polymers and healthcare device technologies. Over more than three decades of research and development—beginning with his Abbott Laboratories–funded doctoral work contributing to the later world-renowned Abbott blood glucose test strips—Professor Lin has developed substantial expertise in the design and commercialisation of healthcare devices. His innovations include a smart polymeric system capable of selectively blocking erythrocytes while permitting plasma flow, achieved through a hybrid hydrophilic–hydrophobic matrix that undergoes structural transitions in response to biological stimuli. Professor Lin has collaborated extensively and successfully with healthcare industries in both the UK and internationally.

Professor Jude A. Oben is an internationally recognised Clinician Scientist and Consultant Gastro-Hepatologist at Guy’s and St Thomas’ NHS Foundation Trust. He holds academic roles in Experimental Hepatology at King’s College London and in Therapeutics at Ningbo University of Technology, China. Professor Oben trained in medicine at the University of Oxford, completed a PhD in Pharmacology at UCL, and undertook research fellowships at Stanford University and Johns Hopkins University, focusing on Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD). His pioneering contributions to liver repair, fibrosis and the trans-generational transmission of obesity and MASLD have earned international recognition, including election as a Sigma Xi Fellow, alongside significant engagement in public health policy on obesity.

Dr Melisa Naranjo Vanegas, based in Columbia,  is a medical doctor and epidemiologist with advanced training in epidemiology, public health and global health from Universidad de los Andes, Colombia. She has led multidisciplinary research across Latin America, integrating clinical, genomic and population-level data to deliver large-scale studies in maternal, paediatric and precision medicine. Her experience includes coordinating multicentre cohorts and genomic validation studies supported by major funders including the NIH, PAHO/WHO, MSD, Illumina and the Ministry of Science of Colombia. With over 20 peer-reviewed publications and active collaborations with academic and healthcare institutions, she has contributed to strengthening research capacity through methodological leadership and evidence-based programme development. She also works internationally as a medical writer, producing clinical guidelines, scientific reports and regulatory-aligned study protocols.

Dr Weidong He completed her PhD in Polymer Chemistry at the University of Leeds in 1995 and is an organic synthesis chemist with over 35 years of applied research and development experience across diverse industrial sectors in the UK and overseas. She has an exceptional track record in the design, synthesis, and evaluation of small-, medium-, and large-scale functional molecules. Dr He is widely regarded as an authority in the synthesis of small and medium functional molecules, as demonstrated by her patented inventions of reactive coloured molecules (e.g., WO02096995, WO0125338, WO0069974, WO0069973). Her expertise also extends to the creation of crosslinkable macromolecules—including porphyrins, porphyrinogens, and their corresponding polymer matrices used as barrier materials—evidenced by her additional patents (e.g., WO9601282, WO9313150, WO9201007).